December 6, 2019
Precision Hematology in Myelodysplastic Syndromes
Precision Hematology in Myelodysplastic Syndromes
Activity Overview
This symposium will describe recent advances in our understanding of the genetic basis of myelodysplastic syndromes and related myeloid neoplasms, and how these advances are being translated into precision medicine approaches to diagnosis, prognostication and treatment for patients with these hematologic malignancies.
Target Audience
This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.
Learning Objectives
- Identify how to use molecular genetics in diagnostic and prognostic evaluation of MDS
- Discuss the fundamental concepts of inherited predisposition to myeloid neoplasms in general and myelodysplastic syndromes in particular
- Identify how to diagnose and treat patients with MDS under the age of 60
- Discuss how to diagnose CCUS
- Discuss how to diagnose clonal monocytosis of clinical significance
- Explain the molecular classification of MDS
- Describe the prognostic significance of germline and somatic mutations in MDS
- List current approaches to treatment of ineffective erythropoiesis in MDS
- List current approaches to personalized treatment in MDS.
Cochairs
Mario Cazzola, MD
Stephen D. Nimer, MD
Speakers
Catherine Cargo, MD
Mario Cazzola, MD
Jane Churpek, MD, MS
Eva Hellstrom-Lindberg, MD, PhD
Luca Malcovati, MD
Stephen D. Nimer, MD
Elli Papaemmanuil, PhD
Outputs
Access to the meeting outputs are available below by clicking on each topic.
Our Supporters
Thank you to Astex Pharmaceuticals, Celgene Corporation, Daiichi Sankyo, Inc, Onconova therapeutics, and Takeda Oncology for supporting this initiative.
